Eledon Pharmaceuticals ELDN Income Statement (2013-2026)

NASDAQ ELDN
$3.04 +0.11 (+3.58%)
As of: Sep 4, 2026 · 2:23 PM EDT
Reported Financials

Eledon Pharmaceuticals Quarterly Income Statement

Periods 52 quarters
Latest Jun 2026

Eledon Pharmaceuticals reported net income of -$31.63M for the quarter ended Jun 2026. This income statement covers 52 quarters of results from Sep 2013 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Income Statement Sep2013 Dec2013 Mar2014 Jun2014 Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Shares Outstanding (Entity)Shares Outstanding (Entity.)
17.88M17.88M17.20M24.76M24.76M24.76M24.76M28.80M37.47M30.27M31.02M48.13M64.93M48.66M77.13M77.16M77.16M75.43M112.42M113.63M
Operating items
Research & DevelopmentR&D
7.66M6.18M6.63M5.74M7.45M7.25M8.11M7.20M7.93M7.07M7.41M10.11M16.52M17.93M13.53M20.28M14.97M17.20M18.23M
Selling, General & AdministrativeSG&A
2.85M3.20M3.22M3.54M3.15M2.79M3.00M3.15M3.27M3.27M3.46M4.40M3.99M6.77M4.43M4.46M4.10M3.98M4.64M
Restructuring CostsRestructuring
Other Operating ExpensesOther Opex
48.65M-54.29M
Operating ExpensesOpex
10.51M9.38M9.86M9.28M10.60M58.69M11.11M10.35M11.20M10.34M10.87M14.50M20.51M24.70M17.96M24.73M19.07M-54.29M21.18M22.87M
Operating IncomeOp. Inc
-10.51M-9.38M-9.86M-9.28M-10.60M-58.69M-11.11M-10.35M-11.20M-10.34M-10.87M-14.50M-20.51M-24.70M-17.96M-24.73M-19.07M-21.18M-22.87M
EBIT
-10.51M-9.38M-9.86M-9.28M-10.60M-58.69M-11.11M-10.35M-11.20M-10.34M-10.87M-14.50M-20.51M-24.70M-17.96M-24.73M-19.07M-21.18M-22.87M
Non-operating items
Interest & Investment IncomeInt & Inv Inc
0.10M
Other Non Operating IncomeOther Non Op Inc.
0.00M0.64M-0.01M0.04M0.13M0.30M0.34M0.78M0.85M0.71M0.57M0.87M1.04M1.44M1.41M1.22M1.05M1.12M0.86M
Non Operating IncomeNon Op. Inc.
Net income details
EBT
-10.50M-9.58M-9.86M-9.25M-10.47M-58.58M-11.11M-10.35M-11.20M-10.34M-10.87M-14.50M-20.41M-24.70M-17.96M-24.73M-19.07M-21.18M-22.87M
Tax ProvisionsTaxes
-0.69M-5.97M
Profit After TaxPAT
-9.82M-8.81M-9.86M-9.25M-10.47M-58.38M-10.77M-65.76M-9.91M-30.10M-23.63M-44.91M76.97M17.05M-6.50M-11.22M-17.46M-10.42M-39.02M-31.63M
Income from Continuing OperationsIncome (Continuing)
-9.82M-3.61M-9.86M-9.25M-10.47M-58.58M-11.11M-10.35M-11.20M-10.34M-10.87M-14.50M-20.41M-24.70M-17.96M-24.73M-19.07M-21.18M-22.87M
Consolidated Net IncomeConsol Net Inc.
-9.82M-3.61M-9.86M-9.25M-10.47M-58.58M-11.11M-10.35M-11.20M-10.34M-10.87M-14.50M-20.41M-24.70M-17.96M-24.73M-19.07M-21.18M-22.87M
Income towards Parent CompanyParent Net Inc
-9.82M-3.61M-9.86M-9.25M-10.47M-58.58M-11.11M-10.35M-11.20M-10.34M-10.87M-14.50M-20.41M-24.70M-17.96M-24.73M-19.07M-21.18M-22.87M
Preferred Dividend PaymentsPref Dividends
Net Income towards Common StockholdersNet Income
-9.82M-3.61M-9.86M-9.25M-10.47M-58.58M-11.11M-10.35M-11.20M-10.34M-19.50M-14.50M6.67M-32.84M-6.00M-11.22M-19.07M-21.18M-31.63M
Additional items
EPS (Basic)
-0.53-0.20-0.55-0.52-0.59-3.28-0.62-0.35-0.30-0.33-0.52-0.270.10-0.67-0.08-0.15-0.25-0.19-0.28
EPS (Diluted)
-0.53-0.20-0.55-0.52-0.59-3.28-0.62-0.35-0.30-0.33-0.52-0.270.10-0.67-0.08-0.15-0.25-0.19-0.28
Shares Outstanding
18.52M18.52M17.91M17.83M17.83M17.86M17.86M30.01M37.47M30.92M37.49M52.85M64.93M48.66M77.13M77.16M77.16M81.84M112.42M113.63M
Shares Outstanding (Diluted)Shares Outstanding (Dil.)
18.52M18.52M17.91M17.83M17.83M17.86M17.86M30.01M37.47M30.92M37.49M52.85M69.35M48.66M77.13M77.16M77.16M81.84M112.42M113.63M
EBITDA
-10.51M-9.38M-9.86M-9.28M-10.60M-58.69M-11.11M-10.35M-11.20M-10.34M-10.87M-14.50M-20.51M-24.70M-17.96M-24.73M-19.07M-21.18M-22.87M
Tax Rate
6.5362.28